API-First vs Vertical: India's Synthetic Biology Moat
India's synthetic biology market is fragmented across fermentation, enzymes, and biopolymers. API-first platforms will win by 2028, not vertical applications. The India Stack playbook applies here.
Get 1 unfair insight every week from India's startup ecosystem.
Read by serious founders and investors. No fluff.
Continue reading with Blog Pass
This piece is part of the Aletheia archive. This week’s drops are free — unlock every sector thesis, deal-flow breakdown and disclosure note with a Blog Pass.
Amit Tyagi
Founder, AletheiaAI & GP, Fitoor Capital
Veteran of India's startup ecosystem. Writing about fundraising, investor psychology, and what it takes to build fundable startups in India.
Run a fundability check
India's only MRE-backed platform for founders and investors. Analyse your deck, find investors, and validate your raise strategy.
Don’t miss the next one
One insight every week. No fluff.
One contrarian insight. Every week. No generic startup advice.
Join founders and investors building with better information.